JPH0967269A - Fruit body tablet of grifola frondosa s. f. gray - Google Patents
Fruit body tablet of grifola frondosa s. f. grayInfo
- Publication number
- JPH0967269A JPH0967269A JP7248597A JP24859795A JPH0967269A JP H0967269 A JPH0967269 A JP H0967269A JP 7248597 A JP7248597 A JP 7248597A JP 24859795 A JP24859795 A JP 24859795A JP H0967269 A JPH0967269 A JP H0967269A
- Authority
- JP
- Japan
- Prior art keywords
- maitake
- tablet
- glucan
- gray
- fruit body
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、マイタケの子実体
に多く含まれるβグルカンを強化配合した錠剤に関する
ものである。TECHNICAL FIELD The present invention relates to a tablet in which β-glucan, which is often contained in fruiting bodies of Maitake, is reinforced and blended.
【0002】[0002]
【発明が解決しようとする課題】従来から茸類であるマ
イタケの子実体はβグルカンを比較的多量に含んでお
り、このβグルカンは抗ガン作用があるとされている。
そして、これを服用に供するためにマイタケの子実体を
乾燥させ、粉砕して粉末にしたものが服用剤として提供
されている。Conventionally, fruiting bodies of Maitake mushrooms, which are mushrooms, contain a relatively large amount of β-glucan, and this β-glucan is said to have an anticancer action.
In order to use this, the fruiting body of Maitake is dried and crushed into a powder, which is provided as a drug.
【0003】しかし、マイタケの子実体に含まれるβグ
ルカンの含有量には個体差があり、栽培条件や生産ロッ
トごとに大きく変動する。即ち含有量の変動幅は、8%
から20%と2.5倍もある。従って、剤として一般に
提供するとしても服用量が一定しないので、信頼できる
薬効を期待することができない。However, the content of β-glucan contained in fruiting bodies of Maitake mushrooms varies from individual to individual, and varies greatly depending on cultivation conditions and production lots. That is, the fluctuation range of the content is 8%
From 20% to 2.5 times. Therefore, even if it is generally provided as a drug, the dose is not constant, so that reliable drug efficacy cannot be expected.
【0004】ところで、βグルカンによって抗ガン効果
を得るためにはマイタケ粉末を1日に4〜6g摂取しな
ければならないとされている。しかし上述したようにマ
イタケ子実体に含まれるβグルカンは個体によって一定
しておらず、マイタケ粉末を4〜6g摂取したとしても
βグルカンが必要量摂取できるとは限らない。また、マ
イタケの子実体にβグルカンが適量含有されているとし
ても、1日に5gを摂取するとすれば250mgの錠剤
にして20錠を服用しなければならず、苦痛が伴う。[0004] By the way, in order to obtain an anti-cancer effect by β-glucan, it is said that 4 to 6 g of maitake powder must be ingested per day. However, as described above, the β-glucan contained in the fruit body of Maitake is not constant depending on the individual, and even if 4 to 6 g of Maitake powder is ingested, the required amount of β-glucan cannot always be taken. Further, even if the fruiting body of Maitake mushrooms contains an appropriate amount of β-glucan, if 5 g is ingested per day, 20 tablets must be taken as 250 mg tablets, which causes pain.
【0005】本発明は上述した現状のマイタケ子実体の
服用に伴う課題を解決するもので、安定した効果が期待
できるマイタケ子実体錠剤を提供することを目的とする
ものである。The present invention solves the above-mentioned problems associated with the current intake of Maitake fruiting bodies, and an object thereof is to provide Maitake fruiting body tablets which can be expected to have a stable effect.
【0006】[0006]
【課題を解決するための手段】本発明では上述した目的
を達成するために、マイタケ子実体の乾燥粉末に、マイ
タケ子実体の乾燥物から抽出したβグルカンを混合する
という手段を用いることとした。また、錠剤成分とし
て、マイタケ子実体粉末を85重量%、βグルカン80
%以上含有の抽出物を10重量%、残部を錠剤の安定剤
とした。さらに、マイタケ子実体粉末のうち、5重量%
をビタミンCに置換するという手段も選択的に用いるこ
ととした。In order to achieve the above-mentioned object, the present invention employs a means of mixing dry powder of Maitake fruit body with β-glucan extracted from the dried product of Maitake fruit body. . Also, as a tablet ingredient, 85% by weight of Maitake mushroom body powder and β-glucan 80
The extract containing 10% by weight or more was 10% by weight, and the rest was a tablet stabilizer. Furthermore, 5% by weight of Maitake mushroom body powder
It was also decided to selectively use the means of substituting V for vitamin C.
【0007】マイタケ子実体は、その含有成分が抗ガ
ン、抗肥満、血糖値調整、血圧降下、コレステロール値
低下、あるいは便秘などに有効であるとされており、特
にその含有成分中のβグルカンが活性成分として特定さ
れている。従って、マイタケ子実体を適量摂取すること
により、これらの症例に有効に機能することができる。
ところで、マイタケ子実体はマイタケの個体差によって
βグルカンの含有量が変動するので、ある程度均一な含
有量を確保するために、マイタケ子実体から抽出したβ
グルカンの抽出物を補強的に配合する。βグルカンを8
0%以上含有した抽出物を採用するのは、錠剤の薬効値
を高い部分で安定させるためである。[0007] Maitake mushroom fruit body is said to be effective in its components for anti-cancer, anti-obesity, blood sugar level control, blood pressure lowering, cholesterol level lowering, constipation, etc. In particular, β-glucan in the components is It is specified as the active ingredient. Therefore, it is possible to effectively function in these cases by ingesting a proper amount of fruiting body of Maitake.
By the way, since the content of β-glucan in Maitake fruit bodies varies depending on individual differences in Maitake, β-glucan extracted from Maitake fruit bodies is required in order to ensure a somewhat uniform content.
A glucan extract is added as a supplement. 8 beta glucans
The reason why the extract containing 0% or more is used is to stabilize the drug efficacy value of the tablet in a high portion.
【0008】ビタミンCはβグルカンの体内への吸収を
促進する効果を有するので、剤としての基本的な効果を
補強する。Vitamin C has the effect of promoting the absorption of β-glucan into the body, thus reinforcing the basic effect as an agent.
【0009】急性毒性を含む毒性については、本発明の
錠剤の基本組成がマイタケの乾燥物であり、マイタケは
古くから食用に供されているものであるから、問題はな
い。また、強化成分であるβグルカンもマイタケ子実体
から抽出したものであるから、同様に問題はない。ビタ
ミンCについても同様である。Regarding toxicity including acute toxicity, there is no problem because the basic composition of the tablet of the present invention is dried maitake mushroom, which has been used for food since ancient times. In addition, since β-glucan, which is a reinforcing component, is also extracted from fruit bodies of Maitake mushrooms, there is no problem. The same applies to vitamin C.
【0010】服用の形態としては、服用量を容易に確認
できるようにするため、錠剤の形態で行うのが好まし
い。服用量は摂取する個体の体重や状態によって異なる
ので、特定できないが、その範囲としては1日2〜4g
を適宜服用する。例えば250mgの錠剤とすれば、1
日8錠から16錠を一度に、あるいは数回に分けて服用
する。副作用や消化器官に対する劇症のおそれはないた
め、服用時期としても空腹時あるいは満腹時を問わな
い。The dosage form is preferably in the form of a tablet so that the dosage can be easily confirmed. The dose varies depending on the weight and condition of the individual who ingests it, so it cannot be specified, but the range is 2 to 4 g per day.
Take as appropriate. For example, for a 250 mg tablet, 1
Take 8 to 16 tablets daily or in several divided doses. Since there is no risk of side effects or fulminant effects on the digestive system, it can be taken on an empty stomach or a full stomach.
【0011】[0011]
【実施例】本発明のマイタケ子実体の乾燥粉末は、舞茸
を熱風乾燥させた後にこれを粉砕して粉状物とした。次
に、βグルカンの抽出法としては、マイタケ子実体の乾
燥粉末を100〜120℃の清水にて加圧熱水抽出を行
い、その上澄み液を減圧濃縮することによって濃縮液を
得た。その後、エタノール分画によってさらに濃縮し、
乾燥物としての粉末を得た。βグルカンの含有比を80
重量%とする手段は、エタノール分画工程で行った。な
お、本発明ではβグルカンを完全に単離する必要はな
く、その含有比を80重量%以上とすることで目的を達
成することができるので、残部の同定は行わなかった。
しかも、抽出母体が食用の舞茸であるので、毒性につい
ては問題はない。EXAMPLE The dried powder of Maitake mushroom body according to the present invention was obtained by drying Maitake mushrooms with hot air and then pulverizing them to obtain a powder. Next, as a method for extracting β-glucan, a dried powder of Pleurotus cornucopiae fruiting body was subjected to pressurized hot water extraction with fresh water at 100 to 120 ° C, and the supernatant was concentrated under reduced pressure to obtain a concentrated solution. Then, further concentrate by ethanol fractionation,
A powder was obtained as a dried product. Beta glucan content ratio of 80
The means for adjusting the weight percentage was the ethanol fractionation step. In the present invention, it is not necessary to completely isolate β-glucan, and the object can be achieved by setting the content ratio to 80% by weight or more, so the rest was not identified.
Moreover, since the extracted mother body is edible Maitake mushrooms, there is no problem with toxicity.
【0012】このようにして得られたマイタケ子実体の
乾燥粉末を80重量%と、βグルカンの抽出粉末を10
重量%に対し、ビタミンCの粉末5重量%を加え、さら
に錠剤の安定剤としてショ糖脂肪酸エステルを3重量
%、および二酸化珪素2重量%加え、均一に混合した
後、打錠機で錠剤を完成した。この成分はビタミンCが
含まれているため、βグルカンの体内への吸収が促進さ
れる。[0012] 80% by weight of the dried powder of fruiting body of Maitake and the extracted powder of β-glucan of 10
To 5% by weight of vitamin C powder, 5% by weight of vitamin C was added, 3% by weight of sucrose fatty acid ester and 2% by weight of silicon dioxide were added as stabilizers of the tablet, and after uniformly mixing, tablets were formed with a tablet machine. completed. Since this component contains vitamin C, absorption of β-glucan into the body is promoted.
【0013】一方、ビタミンCを配合しない錠剤の場合
には、マイタケ子実体の乾燥粉末を省略したビタミンC
の重量比だけ増量することで足り、錠剤の製造方法は上
述の実施例と変わるところはない。On the other hand, in the case of tablets containing no vitamin C, vitamin C obtained by omitting dry powder of Maitake mushroom fruit bodies is used.
It is sufficient to increase the amount by the weight ratio of the above, and the tablet manufacturing method is the same as the above-mentioned embodiment.
【0014】[0014]
【発明の効果】本発明では、マイタケ子実体の乾燥粉末
にβグルカン抽出物を補強的に配合したので、錠剤中に
安定して活性成分を配合することができた。さらに、ビ
タミンCを強化したものについてはβグルカンの体内へ
の吸収が促進されるので、効果の発揮はさらに期待する
ことができる。INDUSTRIAL APPLICABILITY In the present invention, the β-glucan extract is supplementarily added to the dried powder of fruiting body of Maitake mushroom, so that the active ingredient can be stably added to the tablet. Further, since those having enhanced vitamin C promote the absorption of β-glucan into the body, the effect can be expected further.
Claims (3)
実体の乾燥物から抽出したβグルカンを混合したことを
特徴とするマイタケ子実体錠剤。1. A maitake fruiting body tablet comprising a dried powder of a fruiting body of maitake and β-glucan extracted from a dried product of a fruiting body of maitake.
5重量%、βグルカン80%以上含有の抽出物を10重
量%、残部を錠剤の安定剤とした請求項1記載のマイタ
ケ子実体錠剤。2. A maitake fruit body powder is used as a tablet component.
The maitake fruiting body tablet according to claim 1, wherein the extract contains 5% by weight and 80% or more of β-glucan is 10% by weight, and the balance is a tablet stabilizer.
タミンCに置換した請求項2記載のマイタケ子実体錠
剤。3. The Maitake mushroom body tablet according to claim 2, wherein 5% by weight of the Maitake fruit body powder is replaced with vitamin C.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7248597A JPH0967269A (en) | 1995-08-31 | 1995-08-31 | Fruit body tablet of grifola frondosa s. f. gray |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7248597A JPH0967269A (en) | 1995-08-31 | 1995-08-31 | Fruit body tablet of grifola frondosa s. f. gray |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH0967269A true JPH0967269A (en) | 1997-03-11 |
Family
ID=17180492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7248597A Pending JPH0967269A (en) | 1995-08-31 | 1995-08-31 | Fruit body tablet of grifola frondosa s. f. gray |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0967269A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001097881A (en) * | 1999-09-28 | 2001-04-10 | Yukiguni Maitake Co Ltd | Cancer prophylaxis agent, and cancer prophylaxis food or feed all derived from grifola frondosa |
JP2001095522A (en) * | 1999-03-01 | 2001-04-10 | Compex Co Ltd | Method for producing deodorized mushroom powder |
CN104367563A (en) * | 2014-11-18 | 2015-02-25 | 成都医路康医学技术服务有限公司 | Tablet containing grifola frondosa and preparation method thereof |
CN104434849A (en) * | 2014-12-10 | 2015-03-25 | 浙江方格药业有限公司 | Grifola frondosa tablet and preparation method thereof |
WO2018079514A1 (en) * | 2016-10-28 | 2018-05-03 | 株式会社雪国まいたけ | Composition of maitake extract for treatment and/or prevention of herpes infection |
CN117643372A (en) * | 2023-12-08 | 2024-03-05 | 河西学院 | Application of Lyophyllum decastes fruiting body in preparation of Lyophyllum decastes food or lipid-lowering medicine |
-
1995
- 1995-08-31 JP JP7248597A patent/JPH0967269A/en active Pending
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001095522A (en) * | 1999-03-01 | 2001-04-10 | Compex Co Ltd | Method for producing deodorized mushroom powder |
JP2001097881A (en) * | 1999-09-28 | 2001-04-10 | Yukiguni Maitake Co Ltd | Cancer prophylaxis agent, and cancer prophylaxis food or feed all derived from grifola frondosa |
CN104367563A (en) * | 2014-11-18 | 2015-02-25 | 成都医路康医学技术服务有限公司 | Tablet containing grifola frondosa and preparation method thereof |
CN104434849A (en) * | 2014-12-10 | 2015-03-25 | 浙江方格药业有限公司 | Grifola frondosa tablet and preparation method thereof |
WO2018079514A1 (en) * | 2016-10-28 | 2018-05-03 | 株式会社雪国まいたけ | Composition of maitake extract for treatment and/or prevention of herpes infection |
CN117643372A (en) * | 2023-12-08 | 2024-03-05 | 河西学院 | Application of Lyophyllum decastes fruiting body in preparation of Lyophyllum decastes food or lipid-lowering medicine |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101723206B1 (en) | Pills for health supplement food comprising extracts of protaetia brebitarsis larba and manufacturing method for the same | |
CN104187679B (en) | A kind of haematococcus pluvialis agate coffee health products and preparation method thereof | |
KR101054594B1 (en) | Liver Function Enhancer Composition | |
CN108260731A (en) | A kind of nutritive cream for controlling pet dog cat weight | |
KR20160133811A (en) | Breeding Method for Crickets Comprising Ginsenoside Type Saponin and Polysaccharide from Panax ginseng and their Extracts and Food Composition | |
CN102178077B (en) | Feed additive for goose fatted liver yielding Langder geese | |
EP2675296A1 (en) | Freeze dried extract of parkia, preferably of parkia speciosa beans for treatment of diseases such as diabetes mellitus type 2 | |
JPH0967269A (en) | Fruit body tablet of grifola frondosa s. f. gray | |
CN107569608B (en) | Pharmaceutical composition for reducing blood sugar | |
KR20140028293A (en) | A pharmaceutical composition comprising the combined extract of crataegi fructus and citri pericarpium for treating or preventing obesity or lipid-related metabolic disorder | |
KR101878412B1 (en) | Traditional health tea using onion skin and natural materials and its manufacturing method | |
CN105410133A (en) | Cordyceps health maintaining cake and preparing method thereof | |
KR101425477B1 (en) | method for manufacturing Allium hookeri pill, and Allium hookeri pill produced thereby | |
CN104491339A (en) | Seabuckthorn leaf composition for preventing and treating hyperlipidaemia and resisting thrombus and preparation method thereof | |
CN104082747A (en) | Health food with function of improving body immunity and preparation method of health food | |
CN103766500B (en) | A kind of antifatigue milk sheet | |
CN101396056A (en) | Pine-needle tuckahoe teat and preparation method thereof | |
CN110089734A (en) | A kind of bioactivity joins clever black garlic capsule and preparation method thereof | |
RU2203676C2 (en) | Medicinal agent eliciting immunocorrecting effect | |
CN109394799A (en) | Natural drug composition of the extract containing ganoderma lucidum and its preparation method and application | |
CN103461681A (en) | Method for preparing feed additive free of antibiotics | |
CN1827135B (en) | Compound Chinese medicine for resisting-senility and prolonging life | |
JP2014122162A (en) | Muscle building supplement | |
JP4369096B2 (en) | Excipient composition | |
CN104905243A (en) | Peruvian ginseng ostrica cruda composition with weariness resistance function and preparation method of Peruvian ginseng ostrica cruda composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20050322 |
|
A131 | Notification of reasons for refusal |
Effective date: 20050517 Free format text: JAPANESE INTERMEDIATE CODE: A131 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050630 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050726 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050824 |
|
R150 | Certificate of patent (=grant) or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |